Veru Inc. (NASDAQ:VERU - Get Free Report) saw some unusual options trading activity on Tuesday. Stock investors purchased 4,729 put options on the company. This is an increase of approximately 95% compared to the typical volume of 2,430 put options.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the business. MPM Bioimpact LLC raised its holdings in shares of Veru by 53.8% during the 1st quarter. MPM Bioimpact LLC now owns 6,592,727 shares of the company's stock valued at $3,231,000 after purchasing an additional 2,307,362 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Veru by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 2,997,751 shares of the company's stock valued at $1,950,000 after purchasing an additional 57,611 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Veru by 17.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 1,423,288 shares of the company's stock valued at $698,000 after purchasing an additional 206,614 shares in the last quarter. Oppenheimer & Co. Inc. raised its holdings in shares of Veru by 18.3% during the 1st quarter. Oppenheimer & Co. Inc. now owns 1,325,246 shares of the company's stock valued at $650,000 after purchasing an additional 204,660 shares in the last quarter. Finally, PVG Asset Management Corp raised its holdings in shares of Veru by 64.4% during the 4th quarter. PVG Asset Management Corp now owns 1,047,310 shares of the company's stock valued at $681,000 after purchasing an additional 410,340 shares in the last quarter. Institutional investors own 47.16% of the company's stock.
Veru Stock Up 3.2%
Shares of NASDAQ:VERU traded up $0.02 during trading on Friday, reaching $0.62. 2,345,674 shares of the company traded hands, compared to its average volume of 1,909,317. The firm has a fifty day simple moving average of $0.55 and a 200 day simple moving average of $0.60. The firm has a market cap of $91.33 million, a P/E ratio of -2.60 and a beta of -0.80. Veru has a 1-year low of $0.45 and a 1-year high of $1.42.
Veru (NASDAQ:VERU - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 128.51%. As a group, research analysts anticipate that Veru will post -0.22 EPS for the current year.
Veru Company Profile
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Recommended Stories
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
